News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

You are here: epigenomics > News & Investors

News & Investors

07. November 2018

Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results

Read more

31. October 2018

Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon® Colorectal Cancer Screening Blood Test

Read more

29. October 2018

Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection

Read more

22. October 2018

Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®

Read more

08. October 2018

Epigenomics AG: Capital increase through rights issue with subscription rights of existing shareholders

Read more

02. October 2018

Epigenomics AG: U.S. Congress supports CMS coverage of colorectal cancer screening blood tests

Read more